428 related articles for article (PubMed ID: 32169869)
1. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
3. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
[TBL] [Abstract][Full Text] [Related]
4. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
5. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
6. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death.
Guo Y; Qian R; Li Z; Lv T; Yang C; Li W; Pan T; Hou X; Wang Z
Life Sci; 2024 Jul; 348():122687. PubMed ID: 38718856
[TBL] [Abstract][Full Text] [Related]
8. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V; Melaiu O; D'Amico S; Pastorino F; Tempora P; Scarsella M; Pezzullo M; De Ninno A; D'Oria V; Cilli M; Emionite L; Infante P; Di Marcotullio L; De Ioris MA; Barillari G; Alaggio R; Businaro L; Ponzoni M; Locatelli F; Fruci D
J Exp Clin Cancer Res; 2022 Nov; 41(1):326. PubMed ID: 36397148
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Activation of cGAS for Cancer Immunotherapy.
Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
Front Immunol; 2021; 12():753472. PubMed ID: 34899704
[TBL] [Abstract][Full Text] [Related]
10. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
[TBL] [Abstract][Full Text] [Related]
11. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
12. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
13. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
15. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
16. Genetically Edited Cascade Nanozymes for Cancer Immunotherapy.
Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
[TBL] [Abstract][Full Text] [Related]
17. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer.
Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity.
Xie Y; Li K; Liang J; Wang K; Gong Z; Chen X
Int J Pharm; 2024 Apr; 654():123955. PubMed ID: 38423155
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
Lu ZD; Chen YF; Shen S; Xu CF; Wang J
ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
[TBL] [Abstract][Full Text] [Related]
20. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
